Skip to content

Study · Animal study (in vivo) · 2020

8 results

Doxorubicin-induced oxidative stress differentially regulates proteolytic signaling in cardiac and skeletal muscle.

Montalvo RN, Doerr V, Min K, Szeto HH, Smuder AJ

American journal of physiology. Regulatory, integrative and comparative physiology27 Nov 2019Cited by 68 (Europe PMC)

PMID31774307 (opens in a new tab)DOI10.1152/ajpregu.00299.2019 (opens in a new tab)PepBankPUB-31774307
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In doxorubicin-treated animals, SS‑31 abrogated aberrant mitochondrial ROS emission in cardiac muscle.

    In plain wordsIn doxorubicin-treated animals, SS‑31 stopped the abnormal ROS release in heart muscle.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseMitochondrial ROS emission in heart after doxorubicin
    Study

    n: not reported in source

    doxorubicin-treated animals
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    while SS-31 abrogated aberrant ROS emission in cardiorespiratory muscles of DOX-treated animals
    1 context sentence
    Summary · context
    Cause and effect were determined by administration of the mitochondria-targeted peptide SS-31 to DOX-treated animals.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In doxorubicin-treated animals, SS‑31 abrogated aberrant mitochondrial ROS emission in respiratory (diaphragm) muscle.

    In plain wordsIn doxorubicin-treated animals, SS‑31 stopped the abnormal ROS release in breathing (diaphragm) muscle.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseMitochondrial ROS emission in diaphragm after doxorubicin
    Study

    n: not reported in source

    doxorubicin-treated animals
    Outcome group
    Mitochondrial function · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    while SS-31 abrogated aberrant ROS emission in cardiorespiratory muscles of DOX-treated animals
    1 context sentence
    Summary · context
    Cause and effect were determined by administration of the mitochondria-targeted peptide SS-31 to DOX-treated animals.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In the hearts of doxorubicin-treated animals, SS‑31 prevented doxorubicin-induced proteolytic signaling through the autophagy/lysosomal system.

    In plain wordsIn doxorubicin-treated animals, SS‑31 prevented doxorubicin-driven protein-breakdown signaling in the heart.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseAutophagy/lysosomal signaling in heart
    Study

    n: not reported in source

    doxorubicin-treated animals
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the heart, SS-31 prevented DOX-induced proteolytic signaling through the ALS and UPP.
    1 context sentence
    Summary · context
    Cause and effect were determined by administration of the mitochondria-targeted peptide SS-31 to DOX-treated animals.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In the hearts of doxorubicin-treated animals, SS‑31 prevented doxorubicin-induced proteolytic signaling through the ubiquitin-proteasome pathway.

    In plain wordsIn doxorubicin-treated animals, SS‑31 prevented doxorubicin-driven protein-breakdown signaling through the proteasome pathway in the heart.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseUbiquitin-proteasome signaling in heart
    Study

    n: not reported in source

    doxorubicin-treated animals
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the heart, SS-31 prevented DOX-induced proteolytic signaling through the ALS and UPP.
    1 context sentence
    Summary · context
    Cause and effect were determined by administration of the mitochondria-targeted peptide SS-31 to DOX-treated animals.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In the diaphragm of doxorubicin-treated animals, SS‑31 inhibited signaling by the autophagy/lysosomal system.

    In plain wordsIn doxorubicin-treated animals, SS‑31 reduced protein-breakdown signaling by the autophagy system in the diaphragm.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseAutophagy/lysosomal signaling in diaphragm
    Study

    n: not reported in source

    doxorubicin-treated animals
    Outcome group
    Receptor activity and mechanism · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, ALS signaling was inhibited by SS-31 in the diaphragm, but the UPP was not affected.
    1 context sentence
    Summary · context
    Cause and effect were determined by administration of the mitochondria-targeted peptide SS-31 to DOX-treated animals.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In the diaphragm of doxorubicin-treated animals, SS‑31 did not affect the ubiquitin-proteasome pathway.

    In plain wordsIn doxorubicin-treated animals, SS‑31 did not change proteasome-pathway signaling in the diaphragm.

    Peptide
    Elamipretide (SS-31)
    Outcome
    No significant changeUbiquitin-proteasome signaling in diaphragm
    Study

    n: not reported in source

    doxorubicin-treated animals
    Outcome group
    Receptor activity and mechanism · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, ALS signaling was inhibited by SS-31 in the diaphragm, but the UPP was not affected.
    1 context sentence
    Summary · context
    Cause and effect were determined by administration of the mitochondria-targeted peptide SS-31 to DOX-treated animals.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In doxorubicin-treated animals, SS‑31 attenuated the doxorubicin-induced activation of eIF2α S51 unfolded protein response signaling in the heart.

    In plain wordsIn doxorubicin-treated animals, SS‑31 reduced the doxorubicin-driven stress-response signaling in the heart.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseUnfolded protein response eIF2α S51 signaling in heart
    Study

    n: not reported in source

    doxorubicin-treated animals
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    UPR signaling was activated in both muscles at eukaryotic translation initiation factor 2α (eIF2α) S51 in the heart and diaphragm of DOX-treated animals and was attenuated with SS-31 treatment in both tissues.
    1 context sentence
    Summary · context
    Cause and effect were determined by administration of the mitochondria-targeted peptide SS-31 to DOX-treated animals.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In doxorubicin-treated animals, SS‑31 attenuated the doxorubicin-induced activation of eIF2α S51 unfolded protein response signaling in the diaphragm.

    In plain wordsIn doxorubicin-treated animals, SS‑31 reduced the doxorubicin-driven stress-response signaling in the diaphragm.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseUnfolded protein response eIF2α S51 signaling in diaphragm
    Study

    n: not reported in source

    doxorubicin-treated animals
    Outcome group
    Receptor activity and mechanism · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    UPR signaling was activated in both muscles at eukaryotic translation initiation factor 2α (eIF2α) S51 in the heart and diaphragm of DOX-treated animals and was attenuated with SS-31 treatment in both tissues.
    1 context sentence
    Summary · context
    Cause and effect were determined by administration of the mitochondria-targeted peptide SS-31 to DOX-treated animals.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.